Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE 7 versus SPORANOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE 7 versus SPORANOX.
MICONAZOLE 7 vs SPORANOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Inhibits fungal cytochrome P450 (CYP450)-dependent lanosterol 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Apply 200 mg (one full applicator) intravaginally once daily at bedtime for 7 days.
200 mg orally twice daily for 3-7 days; for onychomycosis: 200 mg orally once daily for 12 weeks.
None Documented
None Documented
Terminal half-life 24-30 hours; prolonged in hepatic impairment
The terminal elimination half-life of itraconazole ranges from 21 to 35 hours for single doses, increasing to approximately 34 to 42 hours at steady state. The half-life of the active metabolite, hydroxyitraconazole, is similar. This long half-life allows for once-daily or twice-daily dosing in most indications.
Primarily fecal (~50%) and renal (~<1% unchanged)
Itraconazole is extensively metabolized in the liver via CYP3A4 to active metabolites, including hydroxyitraconazole. The parent drug and metabolites are primarily excreted in feces (approximately 54%) and urine (approximately 35%), with less than 1% of the dose excreted unchanged in urine.
Category A/B
Category C
Antifungal
Antifungal